Colorectal - oncology - SA Health Approved Cancer Chemotherapy Protocol Register

Adjuvant and neoadjuvant

Adjuvant and Neoadjuvant
Protocol	Administration at chemotherapy unit level	Review Date
Adjuvant CAPOX (XELOX) (capecitabine and oxaliplatin)	Medium	February 2023
Colorectal adjuvant capecitabine The SA Health Cancer Drug Committee has approved this protocol for use for the additional indication: Adjuvant high risk stage II proficient mismatch repair colorectal cancer after complete resection of the primary tumour.	Low	February 2023
Colorectal adjuvant de Gramont (modified) (fluorouracil and leucovorin)	Low	February 2023
Colorectal adjuvant FOLFOX6 (Modified) (fluorouracil leucovorin oxaliplatin) The SA Health Cancer Drug Committee has approved this protocol for the additional indication: Neoadjuvant therapy prior to definitive surgery.	Medium²	February 2023
Colorectal adjuvant QUASAR (Modified) fluorouracil leucovorin weekly	Low	February 2023

Metastatic

Metastatic
Protocol	Administration at chemotherapy unit level	Review Date
Advanced or metastatic FOLFIRI (modified) (fluorouracil leucovorin irinotecan)	Medium²	February 2023
Advanced, metastatic or recurrent pembrolizumab	Low	August 2024
Colorectal metastatic capecitabine	Low	February 2023
Colorectal metastatic capecitabine and bevacizumab	Low	February 2023
Colorectal metastatic capecitabine and mitomycin SUPERSEDED The SA Health Cancer Drug Committee has approved this protocol for 3rd or 4th line therapy in advanced colorectal cancer after failure of oxaliplatin and irinotecan based chemotherapy.	Medium	February 2023
Colorectal metastatic CAPIRI (XELIRI) (capecitabine irinotecan)	Medium	February 2027
Colorectal metastatic CAPIRI (XELIRI) (capecitabine irinotecan) and bevacizumab	Medium	February 2027
Colorectal metastatic CAPOX (XELOX) (capecitabine and oxaliplatin)	Medium	February 2023
Colorectal metastatic CAPOX (XELOX) (capecitabine and oxaliplatin) and bevacizumab	Medium	February 2023
Colorectal metastatic cetuximab (two weekly)	Low	February 2025
Colorectal metastatic cetuximab and encorafenib	Low	August 2023
Colorectal metastatic de Gramont (modified) (fluorouracil and leucovorin)	Low²	February 2023
Colorectal metastatic FOLFIRI (modified) (fluorouracil leucovorin irinotecan) and bevacizumab	Medium²	February 2023
Colorectal metastatic FOLFIRI (modified) (fluorouracil leucovorin irinotecan) and cetuximab	Medium²	February 2023
Colorectal metastatic FOLFIRI (modified) (fluorouracil leucovorin irinotecan) and panitumumab. The SA Health Cancer Drug Committee have approved this protocol for the amended indication: Treatment of patients with RAS wild-metastatic colorectal cancer.	Medium²	February 2023
Colorectal metastatic FOLFIRI (modified) (fluorouracil leucovorin irinotecan) and cetuximab (two weekly)	Medium²	February 2023
Colorectal metastatic FOLFOX6 (modified) (fluorouracil leucovorin oxaliplatin)	Medium²	February 2025
Colorectal metastatic FOLFOX6 (modified) (fluorouracil leucovorin oxaliplatin) and bevacizumab	Medium²	February 2023
Colorectal metastatic FOLFOX6 (modified) (fluorouracil leucovorin oxaliplatin) and cetuximab	Medium²	February 2023
Colorectal metastatic FOLFOX6 (modified) (fluorouracil leucovorin oxaliplatin) and panitumumab	Medium²	February 2023
Colorectal metastatic FOLFOXIRI (modified) (fluorouracil leucovorin oxaliplatin irinotecan)	Medium	February 2023
Colorectal metastatic FOLFOXIRI (modified) (fluorouracil leucovorin oxaliplatin irinotecan) with bevacizumab	Medium	February 2023
Colorectal metastatic irinotecan three weekly	Medium	February 2027
Colorectal metastatic irinotecan 2-weekly - *SAHCDC Approved non-eviQ protocol* Colorectal irinotecan 2-weekly protocol (PDF 1171KB)	Medium	December 2024
Colorectal metastatic irinotecan and panitumumab - SAHCDC Approved non-eviQ protocol Colorectal metastatic irinotecan and panitumumab (PDF 1315KB)	Medium	December 2024
Colorectal metastatic panitumumab	Low	February 2023
Colorectal metastatic QUASAR (modified) fluorouracil and leucovorin weekly	Low	February 2023
Colorectal metastatic raltitrexed	Medium	February 2023
Colorectal metastatic raltitrexed and oxaliplatin³. For information on this protocol please contact the SA Health Cancer Drug Committee.	Medium	March 2022
Colorectal metastatic regorafenib³	Low	February 2027
Colorectal metastatic Roswell Park (modified) fluorouracil and leucovorin weekly	Low	February 2023
Colorectal metastatic Roswell Park (modified) fluorouracil leucovorin weekly and bevacizumab	Low	February 2023
Metastatic trifluridine/tipiracil	Low	February 2024

Anal

Anal
Protocol	Administration at chemotherapy unit level	Review Date
Anal advanced cARBOplatin and PACLitaxel	Medium	February 2024
Anal definitive cISplatin and fluorouracil chemoradiation	Medium²	February 2027
Anal definitive mitomycin and capecitabine chemoradiation	Medium	February 2023
Anal definitive mitomycin and fluorouracil chemoradiation	Medium²	February 2023

Rectal

Rectal
Protocol	Administration at chemotherapy unit level	Review Date
Adjuvant CAPOX (XELOX) (capecitabine and oxaliplatin)	Medium	February 2023
Rectal locally advanced capecitabine chemoradiation	Medium	February 2027
Rectal locally advanced fluorouracil (protracted Infusion) chemoradiation	Medium²	February 2023
Rectal neoadjuvant CAPOX (XELOX) (capecitabine and oxaliplatin) The SA Health Cancer Drug Committee have approved this protocol for the amended indication: Neoadjuvant treatment of patients with stage II or III rectal cancer (up to 8 cycles)	Medium	February 2023
Rectal adjuvant FOLFOX6 (modified) (fluorouracil leucovorin oxaliplatin)	Medium	February 2023
Rectal neoadjuvant FOLFIRINOX (modified) (fluorouracil leucovorin irinotecan oxaliplatin)	Medium²	August 2023
Rectal neoadjuvant FOLFOX6 (modified) (fluorouracil leucovorin oxaliplatin) The SA Health Cancer Drug Committee have approved this protocol for the amended indication: Neoadjuvant treatment of patients with stage II or III rectal cancer (up to 12 cycles)	Medium	February 2023

Notes

Permitted to be administered in low-risk units for second and subsequent cycles for patients with ECOG performance status 0 or 1 showing ≤ Grade 1 toxicity
Fluorouracil pumps may be connected/disconnected at low-risk units
Non-formulary drug included in the protocol
Continuation dual treatment with pertuzumab and trastuzumab can be provided to appropriate patients at low-risk chemotherapy units.

Use of the information and data contained within this site or these pages is at your sole risk.
If you rely on the information on this site you are responsible for ensuring by independent verification its accuracy, currency or completeness.
This site includes links to other websites operated by community, business and government.
These linked websites will have their own terms and conditions of use and you should familiarise yourself with these.
All linked websites are linked 'as is' and the Government of South Australia:
- does not sponsor, endorse or necessarily approve of any material on websites linked from or to this Site;
- does not make any warranties or representations regarding the quality, accuracy, merchantability or fitness for purpose of any material on websites linked from or to this Site;
- does not make any warranties or representations that material on other websites to which this site is linked does not infringe the intellectual property rights of any person anywhere in the world; and
- does not authorise the infringement of any intellectual property rights contained in material in other websites by linking this site to those other websites.
If you use automatic language translation services in connection with this site you do so at your own risk.
The information and data on this site is subject to change without notice. The Government of South Australia may revise this disclaimer at any time by updating this posting.
The Government of South Australia, its agents, instrumentalities, officers and employees:
- make no representations, express or implied, as to the accuracy of the information and data contained on this site
- make no representations, express or implied, as to the accuracy or usefulness of any translation of the information on this site or any linked website into another language
- make no representations as to the availability of the site and the availability of websites linked from or to the site
- accept no liability however arising for any loss resulting from the use of the site and any information and data or reliance placed on it (including translated information and data)
- make no representations, either expressed or implied, as to the suitability of the said information and data for any particular purpose
- accepts no liability for any interference with or damage to a user's computer, software or data occurring in connection with or relating to this Site or its use or any website linked to this site
- do not represent or warrant that applications or payments initiated through this site will in fact be received or made to the intended recipient. Users are advised to confirm the application or payment by other means.

Privacy http://www.sahealth.sa.gov.au/wps/wcm/connect/public+content/sa+health+internet/about+us/website+information/privacy

Copyright http://www.sahealth.sa.gov.au/wps/wcm/connect/public+content/sa+health+internet/about+us/website+information/copyright

Disclaimer http://www.sahealth.sa.gov.au/wps/wcm/connect/public+content/sa+health+internet/about+us/website+information/disclaimer

Last updated: 03 Aug 2022